Physiomics (LSE:PYC) has won a £119,000 contract for model-informed drug development work and signed non-binding heads of terms with an unnamed third party to explore commercialising its personalised dosing software. No revenue has yet been agreed under the second arrangement.
What was announced
On 14 October 2026, Physiomics announced two separate developments. The first is a contract win worth £119,000 for model-informed drug development (MIDD) work, including pharmacokinetic/pharmacodynamic (PK/PD) modelling. The second is the signing of non-binding heads of terms with an unnamed third party to explore the marketing and commercialisation of the company's personalised dosing software and associated intellectual property.
The two items are distinct. The contract is an agreed piece of paid work, while the heads of terms are a non-binding framework for discussions that may or may not lead to a commercial agreement.
The contract
The £119,000 contract covers MIDD services. PK/PD modelling describes how a drug moves through the body and how it affects the body over time, and is used by drug developers to support decisions on dosing and trial design. Physiomics did not disclose the identity of the client, the duration of the work or its start date.
Executive Director Mike Whitlow said the contract showed the team's ability to move quickly and deliver.
For a micro-cap company, a contract of this size is a meaningful piece of business, although the announcement did not set the figure against the company's revenue or order book. It also did not say whether the client is a new or existing customer, or whether the work could lead to follow-on projects.
MIDD work of this kind forms part of Physiomics' services business, in which the company applies its modelling capabilities to clients' drug development programmes. That business is separate from the personalised dosing software that is the subject of the heads of terms.
The heads of terms
The non-binding heads of terms are intended to allow Physiomics and the third party to explore how the personalised dosing software and related IP might be marketed and commercialised. The company identified potential areas including the wellness sector and possibly the United States.
Physiomics stressed that no specific application, commercial terms or revenue have been agreed. Any collaboration depends on the parties signing a definitive agreement, and there is no certainty that this will happen. The third party has not been named, and no timetable for reaching a definitive agreement was given.
Existing programmes unaffected
The company said its PREDICT-ONC study is unaffected by the new arrangements. PREDICT-ONC is a grant-funded study conducted with Beyond Blood Diagnostics and Blackpool Teaching Hospitals NHS Foundation Trust. Final findings are expected "in due course", with no specific date given.
Physiomics also said its existing engagement with DoseMe and the DoseMeRx arrangements are unchanged. This indicates that the heads of terms are intended to sit alongside, rather than replace, its current commercial relationships for dosing software.
What to watch next
The key item to follow is whether the non-binding heads of terms progress to a definitive agreement, and, if so, what application, commercial terms and geographic scope it covers. Until such an agreement is signed, the arrangement carries no agreed revenue.
On the services side, investors may look for further detail on the timing of work under the £119,000 contract and on whether additional MIDD contracts follow. The final PREDICT-ONC findings, when published, will also be relevant to how the company presents its personalised dosing technology.
The announcement does not contain financial guidance, and Physiomics (LSE:PYC) has not quantified any expected income from the heads of terms. Readers should treat the potential dosing-software collaboration as exploratory at this stage.






Please wait processing your request...